Section 12
Authors
Petta CA, Obiol Saiz M, Fruzzetti F, Yadav A
Writing support
provided by
Silvia Paz Ruiz
Access to modern contraceptives varies widely across regions, shaped by socio-economic, cultural, and policy-related factors. While some countries have made significant progress, others continue to face substantial barriers, including financial constraints, restrictive laws, religious opposition, and social stigma. The scale of the issue is underscored by the fact that, in 2021, approximately 164 million women of reproductive age worldwide lacked access to the contraception they needed, a significant proportion of whom reside in low- and middle-income countries. Across the globe, marginalised populations are among the most vulnerable; for example, indigenous communities frequently encounter structural barriers to accessing health care, including reproductive services, due to geographic isolation, poverty, and cultural mismatch with mainstream systems [1]. Overcoming these challenges requires more than simply expanding supply; it demands deliberate, equity-focused strategies that recognise and address the specific needs of underserved populations. Ensuring universal access to contraception is not only essential to safeguarding reproductive autonomy but also critical to advancing health equity, gender justice, and sustainable development. As the following section will demonstrate, translating global commitments into tangible outcomes depends on targeted, context-sensitive policies and sustained investment.
Section 01
V1.0 10nov2025
Gemzell-Danielsson K, Yadav A, Petta CA
Family planning, fertility care, and contraceptive care are interrelated yet distinct components of reproductive health, each reflecting evolving paradigms in health policy, human rights, and clinical practice. According to the World Health Organization (WHO), family planning refers to the ability of individuals and couples to anticipate and attain their desired number of children and determine the timing and spacing of pregnancies through the use of contraceptive methods and the treatment of…
Section 02
V1.0 10nov2025
Gemzell-Danielsson K, Sridhar A, Osuga Y, Barriga P
Contraception is a fundamental component of reproductive health, yet its use, acceptance, and outcomes vary significantly across global regions. These differences are shaped by a wide range of cultural, socioeconomic, and policy factors that influence both method preferences and access. From regional variations in contraceptive use to the impact of societal norms, healthcare infrastructure, and religious beliefs, understanding these dynamics is key to…
Section 03
V1.0 10nov2025
Arnal JF, Taylor HS, Osuga Y, Foidart JM
Estrogens exert a wide range of biological effects through complex mechanisms of action that extend beyond reproductive regulation. Their influence spans the cardiovascular, skeletal, dermal, immune, and central nervous systems (Table 1), mediated by both genomic pathways (through direct or indirect modulation of gene transcription) and non-genomic pathways (through rapid, membrane-initiated signalling).
Section 04
V1.0 10nov2025
Stanczyk FZ, Taylor H, Gaspard U
Understanding the pharmacokinetic and metabolic profiles of estrogens is essential for optimisingcontraceptive efficacy and safety. The pharmacokinetic behaviour of estrogens in combined hormonal contraceptives is determined by the interrelated processes of absorption, distribution, metabolism, and excretion (ADME). This section provides an overview of the ADME characteristics of the three main estrogens used in combined oral…
Section 05
V1.0 10nov2025
A Sridhar, K Gemzell Danielsson, U Gaspard, P Barriga, T de Villiers
Estrogen-containing contraceptives are vital for reproductive health across life stages, with natural, body-identical estrogens offering a safer and more metabolically favourable alternative to synthetic formulations, whose unique pharmacological properties ensure effective contraception and therapy with reduced health risks for adolescents, young, and midlife women [1-3]. In adolescents and young adults, COCs with natural estrogens (estradiol [E2] and estetrol [E4]) show benefits…
Section 06
V1.0 10nov2025
Archer D, Mansour DJ, Creinin MD
Unpredictable bleeding is a common concern among users of hormonal contraception and a leading cause of early discontinuation. For combined hormonal contraception (CHC) users, the severity and pattern of bleeding changes depend on the type and dose of estrogen and progestogen, with bleeding often improving with duration of use. While the synthetic estrogen ethinylestradiol (EE) has long been the standard estrogen component, newer formulations…
Section 07
V1.0 10nov2025
Piltonen T, Osuga Y, Bitzer J
While the negative effects of combined oral contraceptives (COCs) often receive considerable attention, their numerous positive effects are frequently underestimated and underreported. Estrogens play a crucial role in the non-contraceptive benefits of COCs, and selecting the appropriate oestrogen-progestin combination can help alleviate symptoms in various clinical scenarios.
Section 08
V1.0 10nov2025
Douxfils J, Gaspard U, Creinin MD
Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is a major global public health issue that contributessignificantly to preventable morbidity and mortality, accounting for one in four deaths globally. Although most commonly associated with older populations, VTE also affects younger women, particularly due to iatrogenic factors such as the use of combined hormonal contraceptives (CHCs). Large observational studies estimate…
Section 09
V1.0 10nov2025
Foidart JM, Piltonen T, Creinin MD
The estrogen and progestin components of combined hormonal contraceptives (CHCs)primarily function to prevent pregnancy by inhibiting ovulation and altering cervical mucus. Menstrual benefits are realised due to the manner in which the hormones limit endometrial development, resulting in reduced menstrual blood loss and alleviation of menstrual pain. CHCs also provide several additional non-contraceptive health benefits, including…
Section 10
V1.0 10nov2025
Piltonen T, Gemzell-Danielsson K, Sridhar A
The specific pairing of estrogens and progestins in a combined oral contraceptive (COC) meaningfully shapes tolerability. In practice, continuation depends less on efficacy than on lived experience, particularly in terms of bleeding patterns, mood stability, and sexual well-being. Most side effects are mild and often settle with continued use or a switch to an alternative formulation. Because tolerability reflects the combined action of both…
Section 11
V1.0 10nov2025
Bitzer J, Fruzzetti F, Yadav A
Contraceptive decision-making is a deeply personal and culturally mediated process shaped by the availability of methods, access to healthcare, and structural inequalitieson one hand, and individual preferences as well as social values on the other hand.
While efficacy, safety and availability are universal priorities, the values and expectations surrounding contraception vary significantly across countries and…
Section 12
V1.0 10nov2025
Petta CA, Obiol Saiz M, Fruzzetti F, Yadav A
Access to modern contraceptives varies widely across regions, shaped by socio-economic, cultural, and policy-related factors. While some countries have made significant progress, others continue to face substantial barriers, including financial constraints, restrictive laws, religious opposition, and social stigma. The scale of the issue is underscored by the fact that, in 2021, approximately 164 million women of reproductive age worldwide lacked access to the…
Section 13
V1.0 10nov2025
Obiol Saiz M, Sridhar A, Piltonen T, Yadav A, Díaz Yamal IJ
The rise of social media has changed how women at different life stages access, interpret, and act on information about contraception. Platforms like YouTube, TikTok, and Instagram have become key in shaping contraceptive choices, often highlighting personal experiences, cultural stories, and misinformation. This influence is powerfulwhere formal sexual education is limited or unavailable. For many, particularly adolescents and marginalised groups, these platforms act as…
Section 14
V1.0 10nov2025
Piltonen T, Gemzell Danielsson K, Petta CA, Black DArnal JF, Taylor HS, Osuga Y, Foidart JM
Environmental pollution has a significant impact on women’s health throughout their lives.
These compounds enter surface water and treated drinking water, where they act as endocrine-disrupting compounds (EDCs), mimicking or blocking natural hormones and disrupting vital biological processes. Their persistence in aquatic environments not only endangers biodiversity but also poses health risks for…
Section 15
V1.0 10nov2025
–
This project is supported by members of the EStrogens and combined oral CONtraceptives Expert Committee (ESONEC), a group of clinical experts and academic advisors from across Europe, Asia, and the Americas.
Section 01
V1.0 10nov2025
Gemzell-Danielsson K, Yadav A, Petta CA
Section 02
V1.0 10nov2025
Gemzell-Danielsson K, Sridhar A, Osuga Y, Barriga P
Section 03
V1.0 10nov2025
Arnal JF, Taylor HS, Osuga Y, Foidart JM
Section 04
V1.0 10nov2025
Stanczyk FZ, Taylor H, Gaspard U
Section 05
V1.0 10nov2025
A Sridhar, K Gemzell Danielsson, U Gaspard, P Barriga, T de Villiers
Section 06
V1.0 10nov2025
Archer D, Mansour DJ, Creinin MD
Section 07
V1.0 10nov2025
Piltonen T, Osuga Y, Bitzer J
Section 08
V1.0 10nov2025
Douxfils J, Gaspard U, Creinin MD
Section 09
V1.0 10nov2025
Foidart JM, Piltonen T, Creinin MD
Section 10
V1.0 10nov2025
Piltonen T, Gemzell-Danielsson K, Sridhar A
Section 11
V1.0 10nov2025
Bitzer J, Fruzzetti F, Yadav A
Section 12
V1.0 10nov2025
Petta CA, Obiol Saiz M, Fruzzetti F, Yadav A
Section 13
V1.0 10nov2025
Obiol Saiz M, Sridhar A, Piltonen T, Yadav A, Díaz Yamal IJ
Section 14
V1.0 10nov2025
Piltonen T, Gemzell Danielsson K, Petta CA, Black D
Section 15
V1.0 10nov2025
–
After submitting your name and email adress, the whitepaper will be downloaded automatically.
Go back